CNS-11

CNS-11 is a preclinical small molecule compound discovered by researchers at the University of California, Los Angeles (UCLA). It was identified through structure-based screening of brain-penetrant molecules, starting from the green tea-derived compound epigallocatechin gallate (EGCG). CNS-11 acts as a dual inhibitor/disaggregator of pathological protein aggregates, specifically targeting microtubule-associated protein tau (tau) fibrils and alpha-synuclein fibrils. It has demonstrated the ability to disaggregate tau fibrils from Alzheimer's disease patient brains and alpha-synuclein fibrils from multiple system atrophy (MSA) patient brains. Additionally, CNS-11 inhibits intracellular seeding in biosensor cells, reduces alpha-synuclein aggregates in *C. elegans*, and exhibits brain permeability in mouse models. It is being investigated for the treatment of tauopathies, such as Alzheimer's disease, and synucleinopathies, including Parkinson's disease and multiple system atrophy.

Other names

CAS 445218-34-8CAS445218-34-8CAS-445218-34-8CNS11CNS-11CNS 11N-mesityl-2-(3-oxoindeno[1,2,3-de]phthalazin-2(3H)-yl)acetamide